Auris Medical to provide update on intranasal betahistine program on Wednesday, October 17, 2018
October 12 2018 - 7:30AM
Zug, Switzerland, October 12, 2018 - Auris
Medical Holding AG (NASDAQ: EARS), a clinical-stage company
dedicated to developing therapeutics that address important unmet
medical needs in neurotology and mental health supportive care,
today announced that it will provide an update on its intranasal
betahistine program, including key results from the second Phase 1
trial, on Wednesday, October 17, 2018. Following the announcement,
Auris Medical's management team will host a live conference call
and webcast at 8:00 am Eastern Time (2:00 pm Central European
Time).
To participate in this conference call, dial 1-877-407-0312
(toll free) or +1 201-389-0899, and enter passcode 13684198. A live
webcast of the conference call can be accessed in the Investor
Relations section of the Auris Medical website at
www.aurismedical.com. A replay will be available approximately two
hours following the live call.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical
company dedicated to developing therapeutics that address important
unmet medical needs in neurotology and mental health supportive
care. The company is focused on the development of intranasal
betahistine for the treatment of vertigo (AM-125) and for the
treatment of antipsychotic-induced weight gain and somnolence
(AM-201). This program is currently in Phase 1. In addition Auris
Medical has two Phase 3 programs under development: AM-111 for
acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner
ear tinnitus. The Company was founded in 2003 and is headquartered
in Zug, Switzerland. The shares of Auris Medical Holding AG trade
on the NASDAQ Capital Market under the symbol "EARS."
Company contact: Hernan Levett, Chief Financial Officer, +41 61
201 1350investors@aurismedical.com
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Apr 2023 to Apr 2024